Clear Street Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $100 to $130.
Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $100 to $130.